Drug Profile
Research programme: antibacterials - Merck/FORMA
Latest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Cubist Pharmaceuticals; FORMA Therapeutics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co